Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

1. Moreau, P.
2. Stewart, K.A.
3. Dimopoulos, M.
4. Siegel, D.
5. Facon, T.
6. Berenson, J.
7. Raje, N.
8. Berdeja, J.G.
9. Orlowski, R.Z.
10. Yang, H.
11. Ma, H.
12. Klippel, Z.
13. Zahlten-Kumeli, A.
14. Mezzi, K.
15. Iskander, K.
16. Mateos, M.-V.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1002/CAM4.2945 GOOGLE SCHOLAR lock_openOpen access editor